NDAINJECTIONINJECTABLE
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESPRIN (triflupromazine hydrochloride) is a first-generation antipsychotic administered by injection, approved in 1958 for the treatment of psychotic disorders and acute agitation. The drug functions as a dopamine antagonist, blocking D2 receptors in the central nervous system to reduce psychotic symptoms.
LOE Approaching
LOE approaching with low competitive pressure (30) suggests declining market relevance and minimal team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VESPRIN represents a legacy asset with minimal career growth potential, offering roles primarily in maintenance-mode commercial execution rather than innovation or expansion. Working on this product would focus on market defense, managed care negotiation, and supply chain management for a declining franchise.
Field Sales RepresentativeBrand Manager (Legacy)
Worked on VESPRIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.